<DOC>
	<DOCNO>NCT00391443</DOCNO>
	<brief_summary>BUILD 3 prospective , multicenter , randomize , double-blind , parallel group , placebo-controlled , event-driven , group sequential , phase III superiority study . The primary objective demonstrate bosentan delay disease worsen death patient Idiopathic Pulmonary Fibrosis .</brief_summary>
	<brief_title>BUILD 3 : Bosentan Use Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent Male female age 18 year old ( female childbearing potential must surgically sterilize use reliable method contraception . ) Proven diagnosis IPF accord American Thoracic Society / European Respiratory Society ( ATSERS ) statement , &lt; 3 year , surgical lung biopsy ( SLB ) Interstitial lung disease due condition IPF . Presence extensive honeycombing ( HC ) baseline highresolution compute tomography ( HRCT ) scan . Severe concomitant illness limit life expectancy ( &lt; 1 year ) . Severe restrictive lung disease . Obstructive lung disease . Diffusing capacity lung carbon monoxide &lt; 30 % predict . Residual volume &gt; = 120 % predict . Documented sustained improvement patient 's IPF condition 12 month prior randomization without IPFspecific therapy . Recent pulmonary upper respiratory tract infection ( 4 week prior randomization ) . Acute chronic impairment ( dyspnea ) limit ability comply study requirement . Chronic heart failure New York Heart Association ( NYHA ) class III/IV know leave ventricular ejection fraction &lt; 25 % . Alanine aminotransferase ( ALT/SGPT ) and/or aspartate aminotransferase ( AST/SGOT ) &gt; 1.5 time upper limit normal range . Moderate severe hepatic impairment . Serum creatinine &gt; = 2.5 mg/dl chronic dialysis . Hemoglobin concentration &lt; 75 % low limit normal range . Systolic blood pressure &lt; 85 mmHg . Pregnancy breastfeed . Current drug alcohol dependence . Chronic treatment follow drug prescribe IPF ( within 4 week randomization ) : oral corticosteroid ( &gt; 20 mg/day prednisone equivalent ) , immunosuppressive cytotoxic drug , antifibrotic drug , chronic use Nacetylcysteine ( prescribe IPF ) . Oral anticoagulant indicate venous arterial thrombotic disease . Treatment glibenclamide ( glyburide ) calcineurin inhibitor ( cyclosporine A , tacrolimus ) 1 week prior randomization . Treatment endothelin receptor antagonist 3 month prior randomization . Participation BUILD 1 trial . Treatment another investigational drug 3 month prior randomization plan treatment . Known hypersensitivity bosentan excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>BUILD 3</keyword>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Tracleer</keyword>
	<keyword>Interstitial Lung Disease</keyword>
	<keyword>bosentan</keyword>
	<keyword>Actelion</keyword>
</DOC>